3 Small Cap Stocks With Robust Returns Approves Stock Split, Check Record Date Here

Three small-cap stocks have approved the stock split. These stocks have given multibagger returns in the 1 and 3 years. These 3 stocks are Veerkrupa Jewellers Ltd, Comfort Fincap Ltd, and Medico Remedies Ltd. Below are the details:

1. Veerkrupa Jewellers Ltd

The stock last traded at Rs 129.35/share, down 4.99% from the previous close. The company operates in jewellery products. It has a market capitalisation of Rs 101.71 crore.

It has given 9.62% positive return in 1 week. In 1 month it gave 29.67% return. In 3 months it gave 105.82% positive return. The stock made its debut on the exchange on 18 July 2022. It has given a massive 404.29% return since the date of listing.

1.1. Veerkrupa Jewellers Ltd Stock Split

The company in its exchange filing to BSE on 9 February 2023, said, "The Board has considered and approved issue of Bonus Shares in the ratio of 2 bonus shares for every 3 existing shares to the shareholders and has also approved Split of nominal value of 1 (one) equity share of Rs. 10/- (Rupees Ten) each into 10 (Ten) equity shares of Rs. 1/- (Rupees One) each subject to necessary permissions and approvals. In-details will be shared shortly."

2. Comfort Fincap Ltd

The stock last traded at Rs 111.70/share. The stock operates in the Financial sector. It has a market capitalisation of Rs 121.21 crore.

It has given 13.17% return in 1 week, 20.76% in 1 month and 54.6% in 3 months, respectively. In 1 year it gave 221.9% It has given a massive 1829.19% return in 3 years. In 5 years it gave 613.74% robust return.

2.1. Comfort Fincap Ltd Stock Split

According to the regulatory filing by the company on February 03, 2023, "Proposal for alteration in the share capital of the Company by sub-division/split of the existing One (1) equity share of the Company having face value of Rs. 10/- (Rupees Ten only) each into Five (5) equity shares of face value of Rs. 2/- (Rupees Two only) each and subject to approval of the shareholders and such authorities as maybe required. The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 regarding subdivision/split of equity shares of the Company is enclosed herewith as Annexure IV."

Furthermore, the company in the filing said that the approval of the stock split is subject to approval from the shareholder. According to the filing, "Alteration of Capital Clause (Clause V) of the Memorandum of Association of the Company on account of sub-division of equity shares, subject to approval of the shareholders of the Company. The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 regarding Amendments to Memorandum of Association of the Company is enclosed herewith as Annexure V"

3. Medico Remedies Ltd

The last traded share price of Medico Remedies is Rs 311.45/share. It is a pharmaceutical sector stock having a market capitalisation of Rs 516.91 crore.

The stock has fallen 0.5% in 1 week and 5.98% in 1 month, respectively. It gave 31.08% return in 3 months. It was listed on 26 May 2022. Since listing, it has given a multibagger return of 157.4%.

3.1. Medico Remedies Ltd Stock Split

According to the regulatory filing by the company on February 2, 2023, "The Board considered the proposal for sub-division of 1 equity share of the Company having face value of ₹10/- each into 5 (Five) equity shares having face value of ₹2/- each, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company. Further, the Board recommended consequential amendments in the Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders of the Company. The record date for the sub-division of equity shares shall be decided by the Board and will be intimated to the exchanges."

Disclaimer

The above-mentioned information is purely informational. Greynium Information Technologies and the Author are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.